Related Experiment Videos
Cisplatin-induced renal effects and thromboxane A2 receptor blockade
G T Dorner1, H Pehamberger, G Kornek
1Department of Clinical Pharmacology, Vienna University Hospital, Austria.
European Journal of Clinical Investigation
|November 28, 1997
Summary
Linotroban, a thromboxane A2 receptor antagonist, did not prevent acute kidney damage from cisplatin chemotherapy. This study found no significant renal protective effect in patients receiving linotroban alongside cisplatin treatment.
Area of Science:
- Nephrology
- Pharmacology
- Oncology
Background:
- Cisplatin chemotherapy is associated with significant nephrotoxicity.
- Thromboxane A2 receptor antagonists are being investigated for potential renoprotective effects.
Purpose of the Study:
- To evaluate the efficacy of linotroban, a thromboxane A2 receptor antagonist, in mitigating cisplatin-induced nephrotoxicity.
- To assess the impact of linotroban on renal function parameters during cisplatin therapy.
Main Methods:
- A randomized, placebo-controlled study involving 25 patients with malignant tumors undergoing cisplatin therapy.
- Linotroban or placebo was administered via continuous infusion for 24 hours, starting 1 hour before cisplatin.
- Glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) were measured to assess kidney function.
Main Results:
- Cisplatin administration led to a decrease in GFR and ERPF in the placebo group (P=0.049).
- In the linotroban group, a similar decrease in GFR was observed (P=0.050), but the reduction in ERPF was not statistically significant (P=0.2).
- No significant difference in the nephrotoxic effects of cisplatin was observed between the linotroban and placebo groups.
Conclusions:
- Linotroban does not appear to be effective in preventing the acute nephrotoxic effects of cisplatin.
- Further research may be needed to explore other therapeutic strategies for cisplatin-induced kidney damage.